image
Healthcare - Biotechnology - NASDAQ - GB
$ 8.73
1.62 %
$ 603 M
Market Cap
-2.59
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BCYC stock under the worst case scenario is HIDDEN Compared to the current market price of 8.73 USD, Bicycle Therapeutics plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BCYC stock under the base case scenario is HIDDEN Compared to the current market price of 8.73 USD, Bicycle Therapeutics plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one BCYC stock under the best case scenario is HIDDEN Compared to the current market price of 8.73 USD, Bicycle Therapeutics plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BCYC

image
$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
35.3 M REVENUE
30.76%
-210 M OPERATING INCOME
-10.49%
-169 M NET INCOME
6.44%
-165 M OPERATING CASH FLOW
-171.70%
-1.24 M INVESTING CASH FLOW
57.84%
520 M FINANCING CASH FLOW
107.88%
3.71 M REVENUE
38.57%
-67.7 M OPERATING INCOME
-5.98%
-51.9 M NET INCOME
-1.03%
-9.4 M OPERATING CASH FLOW
76.41%
-368 K INVESTING CASH FLOW
15.40%
203 K FINANCING CASH FLOW
100.64%
Balance Sheet Bicycle Therapeutics plc
image
Current Assets 929 M
Cash & Short-Term Investments 880 M
Receivables 35.7 M
Other Current Assets 13.4 M
Non-Current Assets 28.3 M
Long-Term Investments 0
PP&E 17.2 M
Other Non-Current Assets 11.1 M
91.92 %3.73 %Total Assets$956.9m
Current Liabilities 67.2 M
Accounts Payable 15.8 M
Short-Term Debt 0
Other Current Liabilities 51.4 M
Non-Current Liabilities 96.6 M
Long-Term Debt 3.99 M
Other Non-Current Liabilities 92.6 M
9.64 %31.40 %56.52 %Total Liabilities$163.8m
EFFICIENCY
Earnings Waterfall Bicycle Therapeutics plc
image
Revenue 35.3 M
Cost Of Revenue 0
Gross Profit 35.3 M
Operating Expenses 245 M
Operating Income -210 M
Other Expenses -40.8 M
Net Income -169 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)35m035m(245m)(210m)41m(169m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-594.96% OPERATING MARGIN
-594.96%
-479.18% NET MARGIN
-479.18%
-21.31% ROE
-21.31%
-17.67% ROA
-17.67%
-22.94% ROIC
-22.94%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bicycle Therapeutics plc
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -169 M
Depreciation & Amortization 7.17 M
Capital Expenditures -1.24 M
Stock-Based Compensation 38.1 M
Change in Working Capital 0
Others -60.3 M
Free Cash Flow -166 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bicycle Therapeutics plc
image
Wall Street analysts predict an average 1-year price target for BCYC of $39.2 , with forecasts ranging from a low of $26 to a high of $55 .
BCYC Lowest Price Target Wall Street Target
26 USD 197.82%
BCYC Average Price Target Wall Street Target
39.2 USD 349.60%
BCYC Highest Price Target Wall Street Target
55 USD 530.01%
Price
Max Price Target
Min Price Target
Average Price Target
555550504545404035353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Bicycle Therapeutics plc
image
Sold
0-3 MONTHS
84.7 K USD 6
3-6 MONTHS
672 K USD 8
6-9 MONTHS
145 K USD 6
9-12 MONTHS
143 K USD 7
Bought
0 USD 0
0-3 MONTHS
21.2 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses. seekingalpha.com - 1 week ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. businesswire.com - 1 month ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. businesswire.com - 1 month ago
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. “In 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati. businesswire.com - 2 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering. businesswire.com - 2 months ago
Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data Bicycle Therapeutics' BT8009 showed promising efficacy and safety in early trials, but mixed results in combination with Keytruda caused significant stock volatility. BT8009 demonstrated a superior safety profile compared to PADCEV, with fewer and milder adverse events due to its shorter half-life and faster elimination. Financially, BCYC is solid with $890 million in cash, providing a runway of 11-12 quarters, though it trades at cash value. seekingalpha.com - 2 months ago
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and. businesswire.com - 3 months ago
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a question-and-answer breakout session at 5:35 p.m. PT. A live webcast of the presentat. businesswire.com - 3 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the company's Board of Directors granted to 12 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 67,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i. businesswire.com - 3 months ago
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Conference Symposium (SABCS) in San Antonio, Texas. The. businesswire.com - 4 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on December 2, 2024, the Compensation Committee of the company's Board of Directors granted to thirteen new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 62,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees ent. businesswire.com - 4 months ago
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABCS. businesswire.com - 5 months ago
8. Profile Summary

Bicycle Therapeutics plc BCYC

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 603 M
Dividend Yield 0.00%
Description Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Contact Babraham Research Campus, Cambridge, CB22 3AT https://www.bicycletherapeutics.com
IPO Date May 23, 2019
Employees 305
Officers Dr. Kevin Lee M.B.A., Ph.D. Chief Executive Officer & Executive Director Mr. Zafar Qadir Chief Legal Officer & General Counsel Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D. Co-Founder & Non-Executive Director Dr. Gillian Langford Head of Clinical and Project Management Ms. Alethia Rene Young Chief Financial Officer Dr. Christian Heinis Scientific Founder Mr. Alistair Milnes Chief Operating Officer Mr. Travis Thompson Senior Vice President, Chief Accounting Officer & Principal Accounting Officer Dr. Michael Skynner B.sc. Ph.d., Ph.D. Chief Technology Officer Ms. Stephanie Yao Senior Vice President of Investor Relations and Corporate Communications